Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines with enhanced costimulation maintain high avidity memory CTL.

Sixun Yang1, James W Hodge, Douglas W Grosenbach

  • 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|September 9, 2005
PubMed
Summary

Enhanced costimulatory vaccines boost memory T cell avidity and survival, improving viral clearance and antitumor responses. Booster vaccinations with TRICOM-enhanced vaccines show superior maintenance and avidity of memory CD8(+) T cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026
Same author

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.

Frontiers in immunology·2026
Same author

Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.

Nature communications·2026
Same author

The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer.

The oncologist·2026
Same author

The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

Cancer immunology, immunotherapy : CII·2025
Same author

Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunity.

Science immunology·2025

Area of Science:

  • Immunology
  • Vaccinology

Background:

  • Antigen-specific cytotoxic T lymphocytes (CTL) avidity is crucial for clearing infections and tumors.
  • Enhanced costimulation in vaccines can improve T cell levels and avidity, but its effect on memory T cell survival is debated.

Purpose of the Study:

  • To investigate the impact of enhanced costimulation on the maintenance and avidity of memory CD8(+) T cells.
  • To evaluate the efficacy of booster vaccinations with enhanced costimulatory molecules in an antitumor context.

Main Methods:

  • Primary vaccination with a recombinant vaccinia virus (rV-) expressing a model antigen and TRICOM (T cell costimulatory molecules).
  • Adoptive transfer of memory CD8(+) T cells followed by booster vaccinations with rF-LacZ or rF-LacZ/TRICOM.
  • Analysis of T cell levels, avidity, cytokine expression (IFN-gamma), and lytic activity.

Related Experiment Videos

  • Antitumor experiments using self-antigen vaccines in tumor-bearing mice.

    • Main Results:

    • Booster vaccinations with rF-LacZ/TRICOM significantly enhanced the maintenance and avidity of memory CD8(+) T cells compared to rF-LacZ alone.
    • TRICOM-enhanced vaccines demonstrated superior functional avidity, including increased IFN-gamma production and lytic activity.
    • Enhanced costimulatory booster vaccinations showed improved antitumor effects in a self-antigen cancer model.

    Conclusions:

    • Booster vaccinations incorporating enhanced costimulatory molecules (TRICOM) are superior for maintaining and enhancing the avidity of memory CD8(+) T cells.
    • These findings have significant implications for designing more effective vaccine strategies for infectious diseases and cancer immunotherapy.